Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy

Cancer Research - United States
doi 10.1158/0008-5472.can-17-3939
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Reactivation of P53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2010English

Dual-Functional Melanin-Based Nanoliposomes for Combined Chemotherapy and Photothermal Therapy of Pancreatic Cancer

RSC Advances
ChemistryChemical Engineering
2019English

Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2–p53 Interaction

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2014English

Discovery and Characterization of Small Molecule Rac1 Inhibitors

Oncotarget
Oncology
2017English

Structures of Low Molecular Weight Inhibitors Bound to MDMX and MDM2 Reveal New Approaches for P53-MDMX/Mdm2 Antagonist Drug Discovery

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2010English

Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases

Nature Chemical Biology
Cell BiologyMolecular Biology
2008English

Targeting P53-Mdm2-MDMX Loop for Cancer Therapy

Sub-Cellular Biochemistry
BiochemistryCancer ResearchCell BiologyMolecular Biology
2014English

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

Cancer Discovery
Oncology
2011English

Discovery of Novel Dual Inhibitors of Receptor Tyrosine Kinases EGFR and IGF-1R

Journal of Enzyme Inhibition and Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy